Results from nearly one-third of hundreds of clinical trials have not been disclosed over the past two years by several of the most prestigious research universities in the U.S., despite federal law requirements, a new analysis has found.
Specifically, findings were not posted for 31 percent — or 140 —of 450 studies that were to have been disclosed in public registries as a result of transparency requirements in the FDA Amendments Act, according to Universities Allied for Essential Medicines, a student-led organization concerned with access to medicines, and TranspariMED, a nonprofit research advocacy group.
About the Author Reprints
